CB 4332

CB 4332 is a first-in-class, engineered, recombinant complement factor I (CFI) protein designed as a therapeutic replacement for individuals with CFI deficiency. It is intended for prophylactic subcutaneous administration, aiming to restore functional CFI levels and regulate the complement cascade to address complement-related disorders. Developed from Catalyst Biosciences' protease engineering platform, CB 4332 has received Rare Pediatric Disease Designation from the FDA for treatment of CFI deficiency, a rare immunologic disorder characterized by recurrent infections and glomerulopathies. As of early 2025, it is in preclinical development with no reported human clinical results or approvals.

Other names

Enhanced CFIEnhanced complement Factor ISQ CB 4332